Abstract

We report a macrocyclic ligand (H3L6) based on a 3,6,10,13-tetraaza-1,8(2,6)-dipyridinacyclotetradecaphane platform containing three acetate pendant arms and a benzyl group attached to the fourth nitrogen atom of the macrocycle. The X-ray structures of the YL6 and TbL6 complexes reveal nine coordination of the ligand to the metal ions through the six nitrogen atoms of the macrocycle and three oxygen atoms of the carboxylate pendants. A combination of NMR spectroscopic studies (1H, 13C, and 89Y) and DFT calculations indicated that the structure of the YL6 complex in the solid state is maintained in an aqueous solution. The detailed study of the emission spectra of the EuL6 and TbL6 complexes revealed Ln3+-centered emission with quantum yields of 7.0 and 60%, respectively. Emission lifetime measurements indicate that the ligand offers good protection of the metal ions from surrounding water molecules, preventing the coordination of water molecules. The YL6 complex is remarkably inert with respect to complex dissociation, with a lifetime of 1.7 h in 1 M HCl. On the other hand, complex formation is fast (∼1 min at pH 5.4, 2 × 10–5 M). Studies using the 90Y-nuclide confirmed fast radiolabeling since [90Y]YL6 is nearly quantitatively formed (radiochemical yield (RCY) > 95) in a short time over a broad range of pH values from ca. 2.4 to 9.0. Challenging experiments in the presence of excess ethylenediaminetetraacetic acid (EDTA) and in human serum revealed good stability of the [90Y]YL6 complex. All of these experiments combined suggest the potential application of H3L6 derivatives as Y-based radiopharmaceuticals.
Short abstract
A new versatile asymmetric ligand based on an 18-membered macrocycle possessing three acetate pendant arms and a benzyl moiety provides fast complexation with both natY(III) and 90Y(III), as well as slow dissociation kinetics. A detailed structural study in the solid state and in solution evidences nona coordination of the metal ion by the ligand, offering good protection from solvent water molecules. These favorable properties make this ligand an attractive candidate to develop yttrium-based radiopharmaceuticals.
Introduction
Coordination chemistry plays a major role in biomedicine, as it provides an effective method for carrying metals inside living organisms allowing to take advantage of the extraordinary properties that are characteristic of some of these elements.1 Nevertheless, the release of free metals into the body is, to say the least, undesirable in most cases.2,3 Consequently, ensuring the stability of these coordination compounds is essential to guarantee their safe delivery and excretion. To achieve this goal, macrocyclic ligands are often the preferred choice when designing this type of compound, since they usually give rise to higher thermodynamic stability, as well as superior kinetic inertness.4−7
Undoubtedly, one of the most significant biomedical applications of macrocyclic complexes can be found in the field of biomedical imaging. With respect to the selection of metals, lanthanides have always been of paramount importance for the design of imaging agents in different techniques,8 and, given their unique luminescence properties (especially in the case of Eu3+ and Tb3+), their suitability for the preparation of optical probes for imaging cells, tissues, and small animals must be highlighted.9,10 In this case, the macrocyclic ligand should be designed not only to ensure the stability of the complex but also to maximize the photoluminescence quantum yield of the emission. As Ln3+ centers are known for their poor extinction coefficients, the ligand assumes the task of absorbing light through a suitable chromophore attached to its structure (commonly known as antenna), with this energy being subsequently transferred to the lanthanide ion. Additionally, it is imperative that the macrocycle wraps the metal competently to avoid solvent coordination and consequent quenching of luminescence.11−14
Although it cannot be considered a lanthanide in its own right, yttrium is generally included in this group and, therefore, macrocycles that coordinate effectively with lanthanide ions are usually appropriate for binding with Y3+.15−17 Nonetheless, for imaging purposes, the interest of this ion resides in its nuclear properties. Thus, the positron emitter 86Y has been attracting attention over the last few years as a candidate for the design of radiopharmaceuticals for positron emission tomography (PET) due to its versatile half-life (14.74 h) and its well-known chelation chemistry. Moreover, the existence of the β– emitter isotope [90Y]-yttrium allows for the design of theranostic agents, making yttrium an extremely interesting option in nuclear medicine.18,19 To construct a metal-based radiopharmaceutical, a bifunctional chelator is typically chosen, which is basically a chelating ligand provided with a linker capable of conjugation to a targeting vector.20,21 It must be noted that time is of the essence when working with decaying nuclides, so even though kinetic inertness with respect to dissociation is still fundamental, matching the kinetics of formation with the lifetime of the radioisotope is of paramount importance as well.22,23
Apart from its decay properties, there are some additional nuclear attributes related to yttrium that can be found useful for medical imaging applications. The only natural isotope of yttrium, 89Y, presents a spin quantum number of 1/2, being therefore considered an NMR-active nucleus. Unfortunately, the extremely low gyromagnetic ratio (γ = 2.0864 MHz/T) and the long longitudinal relaxation times (T1) associated with this nucleus make the acquisition of 89Y NMR spectra an almost unfeasible task.24 Nonetheless, this weakness can be turned into strength thanks to a recently discovered technique: dynamic nuclear polarization (DNP). With the application of DNP-NMR, the unusually long T1 translates into an extended polarization lifetime of nuclear spins, which produces an extraordinary increase in sensitivity. Moreover, 89Y NMR spectra present sharp signals and high sensitivity of the chemical shift to the environment, making 89Y compounds potentially attractive as magnetic resonance imaging (MRI) probes.25−29
Among the macrocyclic systems available, azamacrocycles occupy a distinguished position, given that the nitrogen donor atoms present in their structure can be easily functionalized, enabling the incorporation of pendant arms that can be used to tune and control the properties of the metal, to bind to a targeted biomolecule or simply to add additional coordination positions to increase the denticity of the ligand. Thus, the most popular macrocycles in biomedicine are those arising from the modification of the platforms tacn, cyclen, and cyclam, mainly by the inclusion of acetate pendant arms.4 Nevertheless, inserting pyridine moieties into the macrocyclic backbone may be worth considering since their introduction tends to increase rigidity in the ligand and to cause alterations in its basicity, leading to significant modifications in the thermodynamic and kinetic properties of its complexes.30−33 Accordingly, hexaazamacrocycles derived from the condensation of 2,6-diformilpyridine and ethylenediamine such as those depicted in Chart 1, have proven to successfully host lanthanide ions, due to their spacious macrocyclic cavity and their capacity to satisfy the coordination requirements of these large ions through the functionalization of their four secondary amines.34−43 Furthermore, it has been found that binding constants for H4L1 with large metal ions are considerably high (log K ∼ 22) and promising indications of kinetic inertness also exist for H4L1, L3, and L5 lanthanide complexes.35,40,42
Chart 1. Ligands Discussed in This Work.
Herein, we present a new nonadentate hexaazamacrocyclic ligand containing a benzyl group (H3L6) and report its coordination ability toward the Y3+ ion as well as the luminescence properties of its Eu3+ and Tb3+ complexes. The formation and dissociation kinetics of the Y3+ complex have been studied by spectrophotometric measurements. The structure of the complexes in solution was assessed using a combination of multinuclear (1H, 13C, 89Y) NMR spectroscopy, time-resolved emission spectroscopy, and DFT calculations. We also report the X-ray structure of the Y3+ and Tb3+ complexes. Attention should be devoted to alkylation with the benzyl moiety, which could be selectively reversed through hydrogenation. As a result, once the secondary amine is recovered, it could be functionalized a second time with a group of a different nature, such as a linker capable of bioconjugation with a relevant macromolecule, or a more efficient antenna. Another possibility for functionalization is through the para-carbon of this moiety, proving once more that this platform is quite versatile.44 Consequently, ligand H3L6 is expected to be a competent precursor of bifunctional chelators for Y-based radiopharmaceuticals as well as a suitable chelating agent for lanthanides for optical imaging.
Results and Discussion
Synthesis of the Ligand and Metal Complexes
The preparation of ligand H3L6 was achieved by following the synthetic procedure described in Scheme 1. Synthesis of the parent macrocycle 1 was completed by [2 + 2] condensation of ethylenediamine and 2,6-diformylpyridine, using BaCl2 as a template agent, and subsequent reduction of imine moieties with sodium borohydride, as previously reported.46 To obtain a nonadentate ligand, asymmetric functionalization of one NH group was carried out with benzyl bromide in water under controlled pH conditions. In this way, the monosubstituted derivative, compound 2, was obtained. This allowed the introduction of three coordinating pendants arms by N-alkylation with tert-butyl 2-bromoacetate and later hydrolysis with TFA, to finally obtain ligand H3L6 with a 6% overall yield starting from macrocycle 1 (three steps). This moderate result arises because of the poor yield achieved during the initial alkylation with benzyl bromide. Nevertheless, it must be taken into consideration that upon purification in this step, a large amount of unreacted parent macrocycle 1 was recovered, thereby compensating for the low efficiency of the procedure to some extent.
Scheme 1. Synthetic Procedure for the Preparation of LnL6 Complexes.

(i) BaCl2, MeOH, reflux, 4 h; (ii) NaBH4, MeOH, 0 °C; (iii) benzyl bromide, H2O, pH = 5–6; (iv) BrCH2COOtBu, K2CO3, CH3CN; (v) CF3COOH, CH2Cl2; (vi) Ln(OTf)3/YCl3, DIPEA, 1-butanol.
The reaction of H3L6 with Ln(OTf)3 (Ln = Eu or Tb) or YCl3 salts in 1-butanol in the presence of DIPEA as a base afforded the corresponding charge-neutral LnL6 complexes in good yields (ca. 70%). The high-resolution mass spectra (ESI+) confirm the formation of the complexes (Figure S1, Supporting Information).
X-ray Crystal Structure Studies
Slow evaporation from aqueous solutions of the Y3+ and Tb3+ complexes provided colorless block-like crystals suitable for X-ray analysis. Figure 1 displays views of the molecular structures, while bond distances of the metal coordination environments are shown in Table 1. As it can be observed, ligand H3L6 coordinates to the metal centers through the six nitrogen atoms located in the macrocyclic backbone and the three oxygen atoms from the acetate pendant arms, thus resulting in a coordination number of nine. The chelate rings formed by the coordination of the ethylenediamine moieties adopt identical conformations, which can be described as λλ or δδ. In YL6, the two centrosymmetrically related enantiomers are present in the crystal lattice. Crystals of the TbL6 contain both the λλ and δδ isomers in the asymmetric unit, presenting slightly different bond distances and angles. It has been shown that this type of arrangement favors the formation of a smaller macrocyclic cavity and, therefore, of shorter bonds.38,39 With respect to the relative disposition of the pyridyl units, it is known that ligands containing two pyridine moieties connected by an ethylenediamine bridge can present two types of conformations: the twist-wrap (tw), in which the planes that define the pyridyl entities are relatively twisted to each other, and the twist-fold (tf), where in addition to the twisting, an overall folding of the ligand over the metal is observed (Figure S2).47 In this case, the complex exhibits a twist-fold conformation, which is evidenced by the lack of linearity of the N(4)–Y(1)–N(1) angle (148.5°). Once again, this is not surprising, as this kind of disposition has been previously observed in similar structures displaying nine-coordinate geometry.36
Figure 1.
ORTEP45 view of the structure of the YL6 and TbL6 complexes (50% ellipsoid probability). Hydrogen atoms and water molecules are omitted for simplicity.
Table 1. Bond Distances (Å) of the Metal Coordination Environments in LnL6 Complexes (Ln = Y or Tb).
| Y(1)–O(1) | 2.3019(17) | Tb(1)–O(1) | 2.320(4) |
| Y(1)–O(5) | 2.3019(15) | Tb(1)–O(5) | 2.382(6) |
| Y(1)–O(3) | 2.3097(16) | Tb(1)–O(3) | 2.315(2) |
| Y(1)–N(1) | 2.5170(19) | Tb(1)–N(1) | 2.534(2) |
| Y(1)–N(4) | 2.5191(17) | Tb(1)–N(4) | 2.518(5) |
| Y(1)–N(5) | 2.5863(16) | Tb(1)–N(5) | 2.664(5) |
| Y(1)–N(6) | 2.6249(17) | Tb(1)–N(6) | 2.700(5) |
| Y(1)–N(3) | 2.6370(18) | Tb(1)–N(3) | 2.582(5) |
| Y(1)–N(2) | 2.6574(18) | Tb(1)–N(2) | 2.601(7) |
The metal–N distances involving the N atoms of the pyridine units are similar to those observed for other nine-coordinated complexes of these metal ions containing pyridine units.48−51 The distances to the amine donor atoms of the macrocycle and the oxygen atoms of the carboxylate groups are also within the normal range observed for complexes with polyaminocarboxylate ligands.52−55 The coordination polyhedron around the metal ion can be best described as a tricapped trigonal prism (Figure 2). This is confirmed by the quantitative analysis carried out with the aid of the SHAPE program,56−60 which provides shape measures of 1.72 and 1.81 for YL6 and TbL6, respectively (a shape measure of 0 indicates a coordination polyhedron fully coincident with the reference polyhedron, while the maximum value of the shape measure is 100). The upper tripod of the trigonal prism is defined by the oxygen atoms of carboxylate groups O(5) and O(3) and the amine nitrogen atom N(5), while the lower tripod is delineated by N(1), N(3) and O(1). These two triangular faces are nearly parallel, intersecting at 4.0 (YL6) and 4.2° (TbL6). The N donor atoms (N(2), N(4), and N(6)) occupy the capping positions, defining N–(Y,Tb)–N angles in the range 117.3–122.8°, and thus are very close to the ideal values (120°).
Figure 2.

View of the tricapped trigonal prismatic coordination around the metal ion in YL6.
Photophysical Properties of the Eu and Tb Complexes
The UV–vis absorption spectra of the TbL6 and EuL6 complexes in ca. 10–4 M aqueous solution (pH ∼ 7) are depicted in Figure 3. In both cases, the absorption spectra consist of one broad band with a maximum at 268 nm that can be assigned to the π → π* transition centered on the aromatic units of the ligand. Excitation into this absorption band led to the characteristic Ln3+ emission spectra displayed in Figure 3. Thus, TbL6 luminescence gives rise to a set of distinctive narrow bands located between 485 and 655 nm corresponding to the metal-centered 5D4 → 7FJ transitions (J = 6–3), the most intense being placed at 542 nm (J = 5), as expected.61 On the other hand, the emission spectrum of EuL6 shows an array of bands in the range of 580–710 nm, in agreement with the typical 5D0 → 7FJ transitions of this ion (J = 0–4). Particular attention must be given to the 5D0 → 7F0 transition band, whose relatively high intensity is an indication of the low symmetry of the complex. This statement is also supported by the high 5D0 → 7F2/5D0 → 7F1 intensity ratio, which is known to be strongly correlated with a low level of symmetry. In addition, it must be highlighted that the spectrum shows a single 5D0 → 7F0 transition, as can be predicted due to the nondegeneracy of the 5D0 and 7F0 levels, suggesting the existence of a single Eu3+ species in solution. This is in accordance with the splitting patterns observed for 5D0 → 7F1 and 5D0 → 7F2 transitions since, due to the Stark effect, they can split at most into three and five components, respectively, for a single emitting compound.61,62 The presence of three components for the 5D0 → 7F1 transition is also clearly indicative of a low symmetry of the crystal field created by the ligand.62 The ten-coordinate [EuL3]3+ complex, which presents D2 symmetry in solution, presents two components for the 5D0 → 7F1 transition, as well as unusually intense 5D0 → 7F5 and 5D0 → 7F6 transitions that are not observed for EuL6.42
Figure 3.

UV–vis absorption (dotted lines), excitation, and emission spectra of TbL6 (top) and EuL6 (bottom), recorded in H2O solution (10–4 M, pH ∼ 7) at room temperature.
The excitation spectra recorded for both TbL6 and EuL6 complexes upon metal-centered emission are very similar to the corresponding absorption spectra, which indicates that the aromatic moieties in the ligand provide an efficient energy transfer to the metal center.64 To determine the hydration state of TbL6 and EuL6 complexes, their luminescent lifetimes were measured upon emission at 617 and 542 nm, respectively, in both H2O and D2O solutions. The observed emission decays were fitted to monoexponential decay curves (Figure S3), and the resulting lifetime values were collected in Table 2. Calculation of the number of water molecules was possible through the use of Beeby63 and Horrocks65 equations, which unambiguously led to hydration numbers of zero in both cases. The lifetimes of TbL6 measured in H2O and D2O solution are very similar, which leads to a small negative q value calculated with the expression provided by Beeby.63 Thus, it can be concluded that the ligand is able to satisfy the coordination requirements of these ions, preventing solvent molecules from binding to the metal center and therefore fulfilling one of the most important conditions for becoming part of a suitable fluorescent probe.
Table 2. Selected Photophysical Parameters for TbL6 and EuL6 Complexes in Aqueous Solution.
| λmax (ε)a | ϕH2O (%) | τH2O (ms) | τD2O (ms) | qb | |
|---|---|---|---|---|---|
| Tb | 268 (9900) | 60 | 2.41 | 2.63 | –0.1 |
| Eu | 268 (8500) | 7.0 | 1.18 | 1.64 | 0.0 |
λmax, nm; ε, M–1 cm–1.
Hydration number calculated according to ref (63).
The emission quantum yields of both TbL6 and EuL6 have been measured in 0.1 M Tris-buffered aqueous solutions at pH = 7.4 using Eu3+ and Tb3+tris(dipicolinates) as standards.66,67 Predictably, TbL6 presents a quantum yield (ϕH2O = 0.60) that is far superior to that observed for EuL6 (ϕH2O = 0.07), likely because the energy of the ligand-centered triplet state presents a considerably higher energy than the emissive 5D0 level of Eu3+. This is indeed expected, as the excited triplet state of pyridine (32 260 cm–1)68 is much higher in energy that the 5D0 level of Eu3+ (∼17.240 cm–1), while the optimal triplet state energy for efficient energy transfer was found to be 20 000–23 000 cm–1.69 The quantum yield determined for TbL6 is very high, comparable to those determined for q = 0 complexes containing picolinate moieties. Furthermore, the (long) lifetime of the 5D4 excited state of Tb (2.41 ms) is also close to the values reported for highly luminescent TbIII complexes that lack water molecules in the inner coordination sphere.31,70−74
The quantum yield determined for EuL6 (7%) is comparable to that of [EuL3]3+ and represents a ∼4-fold increase with respect to [EuL5]3+.42,43 This can be attributed to the quenching effect of the hydroxyl groups of the ligand coordinated to the metal ion in the latter. The [EuL4]3+ complex displays a considerably lower quantum yield (0.1%) associated with the quenching effect of an excited charge transfer state.43
To gain further understanding of the energy transfer process in EuL6, the metal-centered emission quantum yield was calculated following the procedure developed by Werts et al.75 Unfortunately, this method can only be applied to Eu3+ complexes, as it is based on the strong magnetic dipole nature of the 5D0 → 7F1 transition found in these compounds. Therefore, the intensity of this band can be considered independent of the chemical environment of the metal center and eq 1 can be applied for the calculation of the radiative lifetime τR, where AMD,0 = 14.65 s–1 is the spontaneous emission probability of the 5D0 → 7F1 transition, n is the refractive index of the medium (1.333 for water at 589.3 nm), and Itot/IMD is the ratio of the integrated corrected emission spectra to the area of the 5D0 → 7F1 transition.66,73,75
| 1 |
The value of 6.55 ms found for τR is similar to those reported in the literature for nine-coordinated EuIII complexes.76−80 The quantum yield of the luminescence step (ϕEu) can be subsequently obtained using eq 2 since the lifetime of the Eu complex in water (τH2O) is known (Table 2).
| 2 |
This analysis gives ϕEu = 0.18, which yields a sensitization efficiency (ηsens) of 0.39 using eq 3. This suggests that the EuL6 complex presents a modest efficiency of the energy transfer taking place from the excited states of the ligand.72,73 Nevertheless, this analysis should be taken with caution, as AMD,0 values that depart significantly from that proposed by Werts were recently determined.81
| 3 |
Solution Structure
The diamagnetic character of YL6 allowed for a more thorough analysis of its solution structure using NMR spectroscopy (1H, 13C, and 89Y). A rather complex 1H NMR spectrum was found for YL6 due to the low symmetry of the molecule (C1). Nonetheless, a comparison with the spectra of the free ligand (Figure S4) corroborates the formation of the complex, not only by the chemical shifts that can be observed but also by the extensive increment in the number of signals caused by the increase in the rigidity of the molecule upon coordination. The 13C{1H} NMR spectrum (Figure S5) exhibits the 29 signals expected for a single species in solution. Interestingly, two of the signals arising from carbonyl groups appear as doublets because of coupling with 89Y (2JC-Y ∼ 2 Hz), evidencing the coordination of the acetate groups to the metal center.
The 89Y NMR shift of the YL6 complex was measured using 1H,89Y HMQC experiments, which provide easy access to 89Y NMR shifts, avoiding the long acquisition times required to obtain conventional 89Y NMR spectra.24 The 1H,89Y HMQC spectrum showed cross-peaks relating the 89Y nuclei with several proton nuclei of the ligand, providing an 89Y NMR chemical shift of 154.7 ppm (Figure 4). The 89Y shifts were found to be very sensitive to the number and nature of the donor atoms coordinated to the metal ion, but rather insensitive to the coordination geometry. Indeed, a relationship between the observed 89Y NMR shifts and nature of the donor atoms of the ligand has been established from the analysis of chemical shift data of a wide range of complexes with polyaminopolycarboxylate ligands82
| 4 |
where A is an empirical constant that was determined to be 863 ppm; SNam, SNpy, and SOc represent the shielding contribution of amine nitrogen atoms, pyridyl nitrogen atoms, and carboxylate oxygen atoms, respectively; and nNam, nNpy, and nOc are the number of donor atoms of each type. Using SNam = 68.1, SNpy = 85.7, and SOc = 94.0, with nNam = 4, nNpy = 2, and nOc = 3, we obtained a calculated 89Y shift of δcalc = 137 ppm, which is in good agreement with the experimental shift. These results unambiguously confirm the coordination of the ligand to the metal ion through its N6O3 donor set and exclude the presence of coordinated water molecules (a coordinated water molecule contributes with ca. 107 ppm to the shielding of the 89Y resonance).82
Figure 4.

1H,89Y HMQC NMR spectrum of YL6 recorded in D2O solution (pH ∼ 7.0, 25 °C).
DFT calculations were performed for the LnL6 systems (Ln = Eu, Tb, and Y) with the purpose of understanding the geometries exhibited by these compounds. As previously stated, this type of systems can present a twist-wrap (tw) or a twist-fold (tf) conformation depending on the relative disposition of the pyridyl units. Adopting one or another can induce important changes in the properties of these compounds, and therefore a comparative study between both geometries was conducted. The calculated geometries obtained for YL6 are shown in Figure S2, while bond lengths of the metal coordination spheres found for all of the systems are listed in Table S1 (Supporting Information). An excellent agreement was found for the calculated bond distances with respect to the values obtained by means of X-ray diffraction for the twist-fold conformation of the YL6 complex. The calculated free energies favor the twist-fold conformation for the three complexes, with ΔGo,calc= ΔGo(tw) – ΔGo(tf) values of 1.8, 2.9, and 4.1 kcal mol–1 for EuL6, TbL6, and YL6, respectively. Thus, the twist-fold conformation is increasingly stabilized as the ion size decreases. A quick analysis of the bond lengths reveals that the twist-fold arrangement allows for shorter bonds and this reduction with respect to the twist-wrap disposition becomes more pronounced with smaller metal centers. This is in line with the behavior mentioned above for related compounds,38,39 which evinces that the ligand changes its conformation as the radius of the metal ion decreases so the macrocyclic cavity is reduced, and therefore shorter bonds are favored. Relativistic DFT calculations using the DKH2 Hamiltonian (see computational details below) and the methodology described previously provided calculated 89Y NMR shifts of 154.6 and 120.9 ppm for the twist-fold and twist-wrap forms, respectively. The first value is in excellent agreement with the experimental value of 154.7 ppm, which confirms that the YL6 complex adopts a twist-fold structure in solution.
Dissociation and Formation Kinetics
A high stability of the complex is usually the most crucial requirement for in vivo applications of coordination compounds, as both the free ligand and the metal ion are often toxic. Nonetheless, even though thermodynamic parameters are important aspects to evaluate their stability, nowadays it is widely recognized that a slow dissociation of the complex is more important than a high stability constant.23 Acid decomplexation experiments have become a popular method to preliminarily assess the kinetic inertness of coordination compounds as well as to provide a means of comparison between different ligands. Since most complexes dissociate easily under strongly acidic conditions, the acid-catalyzed process is the main dissociation pathway found for the macrocyclic complexes usually employed for this type of applications.51 ,72 ,83 Accordingly, the acid-catalyzed dissociation rate of YL6 was studied at 25 °C in 0.1 to 2.4 M HCl solutions. The absorption spectra of the ligand and its Y3+ complex are noticeably different, as a bathochromic shift can be detected upon coordination (Figure S6). Hence, the dissociation process has been studied following the variations in absorbance at 268 nm.
Figure 5 shows the plot of the observed dissociation rates (kobs) vs HCl concentration, which indicates the existence of a linear correlation between these two parameters. Therefore, the experimental values obtained could be fitted to eq 5
| 5 |
where k0 is a constant that describes the spontaneous dissociation, while k1 characterizes the specific acid-catalysis dissociation. These results suggest that the dissociation occurs through the formation of a monoprotonated species, probably by protonation of one of the acetate pendant arms followed by proton transfer to one of the N atoms of the macrocyclic ring, subsequently displacing the metal ion from the macrocyclic cavity.83 The fitting procedure of the data yields a negligible (within statistical error) value for k0, which is a sign of the minor importance of spontaneous dissociation in the process, as expected under strongly acidic conditions, where protonation is favored. Consequently, the data were analyzed setting k0 to zero, obtaining a value for k1 = (1.13 ± 0.02) × 10–4 M–1 s–1.
Figure 5.

Dissociation rates (kobs) determined for YL6 as a function of HCl concentration (25 °C).
The values of the rate constants listed in Table 3 indicate that YL6 presents a higher kinetic inertness than YPCTA83 and YDO3A.86 The rate constant characterizing the proton-assisted dissociation pathway k1 is 1 order of magnitude lower for YL6 than for YPCTA, while YDO3A is even more labile under acidic conditions. The half-lives of these complexes calculated from the rate constants confirm the higher inertness of YL6 compared with YPCTA and YDO3A, indicating that YL6 presents a remarkable kinetic inertness with respect to complex dissociation. The GdDOTA complex is however more inert than YL6.
Table 3. Dissociation Rates and Half-Lives (t1/2) of YL6 and Related Complexes.
| k0 (s–1) | k1 (M–1 s–1) | t1/2 (s)e | |
|---|---|---|---|
| (L6)3– | 0 | 1.13(2) × 10–4 | 6.1 × 103 |
| PCTA3–a | 0 | 1.07 × 10–3 | 1.2 × 103 |
| DOTA4–b,c | 5 × 10–10 | 2 × 10–6 | 3.5 × 105 |
| DO3A3–d | 0 | 5.2 × 10–2 | 13 |
Ref (83). Second-order dependence on proton-ion concentration with third-order rate constant k2 = 6.32 × 10–4 M–2 s–1 was observed.
Data for the Gd complex from ref (84).
Kinetic data for the [90Y]YDOTA– complex at 310 K were reported in ref (85).
Data from ref (86).
Calculated at [H+] = 1 M as t1/2 = ln 2/kobs.
The rates of complexation of Y3+ by the L6 ligand were assessed in aqueous solutions buffered at pH values in the range 4.7–5.4. Pseudo-first-order conditions were ensured using an excess of the metal ion (10–40 equiv). The reaction was followed by monitoring the changes in the absorption spectrum of the ligand caused by metal complexation. The reaction was found to be very fast under these conditions, as it was nearly complete (∼90%) within only one minute (Figure S7). However, given the faint spectral changes caused by complexation, we also performed kinetic experiments using Tb3+ and luminescent measurements. These results confirmed a very fast complexation process, which is complete within less than one minute. Thus, these results indicate that the complexes of L6 are formed very quickly, in contrast to the corresponding DOTA derivatives and non-macrocyclic rigidified DTPA derivatives, as it has been shown that labeling of these ligands with 86/90Y-nuclides required either rather harsh conditions (heating at 75–90 °C) or extended reaction times.23
Radiolabeling Experiments
All of the results above prompted the assessment of the suitability of H3L6 for the preparation of 90Y-based radiopharmaceuticals. The influence of reaction conditions for radiolabeling of H3L6 with yttrium-90 was ascertained by varying the reaction time, temperature, ligand concentration, and pH (Figure 6). The ligand (1.26–126 μg; 0.002–0.2 μmol) was dissolved in ethanol and then reacted with yttrium-90 diluted in various acetate buffers. After 5 min, the radiochemical yield reached 86.9 ± 2.26% at RT and 98.6 ± 0.14% by heating to 80 °C (Figure 6A). Heating at least to 40 °C seems to be necessary to obtain a sufficient RCY but heating over 60 °C does not improve this value (Figure 6B). With a ligand concentration below 1 mM, heating to 40 °C appears to be insufficient, while heating to 60 °C leads to a better RCY (Figure 6C). [90Y]YL6 can be synthesized over a broad range of pH (Figure 6D). Radiolabeling results confirm those obtained with 89Y, since [90Y]YL6 is almost quantitatively formed in 5 min at pH = 5.2, at 60 °C (RCY = 95.5 ± 0.57%). HPLC analyses indicate [90Y]YL6 is the sole product formed (Figure S8). Fast reaction kinetics is an advantage when preparing radiopharmaceuticals, especially if working with short-lived isotopes. The performance of H3L6 in terms of radiolabeling efficiency with the [90Y]Y3+ ion is similar to those reported for PCTA analogues containing picolinate units replacing carboxylate pendant arms.31 In contrast, the formation of [90Y]YDOTA requires heating to 60 °C at pH 7.5.87
Figure 6.
(A) 90Y-radiolabeling kinetics (CL = 1 mM, pH 5.2, 20, and 80 °C), (B) variable temperature (CL = 1 mM, pH 5.2, t = 15 min), (C) variation of the ligand concentration (pH 5.2, t = 15 min, 40 and 60 °C), and (D) pH variation, using 1 M acetate buffers (CL = 1 mM, t = 15 min, 60 °C).
[90Y]YL6 Stability
The stability of [90Y]YL6 in a competitive medium (ethylenediaminetetraacetic acid (EDTA) 100 mM) and in human serum was investigated. For these studies, [90Y]YL6 was prepared using optimized conditions. A solution of [90Y]YL6 was either diluted with an aqueous solution (v/v: 1/1) containing a large excess of the competitive EDTA ligand (100 equiv) or in 1 mL of human serum. The mixtures were incubated at 37 °C. Aliquots were taken at different time points (0, 1, 2, 5, 24, 48, and 120 h for the EDTA challenge; 0, 24, 48, 72, 96, and 168 h for serum stability) and analyzed by thin-layer chromatography (TLC). The evolution of the RCP (%) over time is represented in Figure 7.
Figure 7.

Stability of [90Y]YL6 (10–20 μM) in an excess of EDTA (100 equiv) and in human serum.
Radiochemical purity (RCP) of [90Y]YL6 recorded over time indicates that the complexes remain remarkably stable in the presence of EDTA. There is no dissociation or transchelation for up to 5 days, which confirms the high kinetic inertness of the YL6 complex (Figure S9). Similarly, [90Y]YL6 remains stable for over a week in the presence of human serum.
Conclusions
We have shown that ligand H3L6 can be regarded as a suitable platform for the coordination of large metal ions such as Y3+, Tb3+, and Eu3+. According to the kinetic studies, the studied complexes show good inertness with respect to dissociation, making it possible to consider these compounds for biomedical applications. The remarkable kinetic inertness of these complexes is particularly striking considering the large size of the 18-membered macrocyclic unit of the ligand. Indeed, to the best of our knowledge only 12-membered macrocycles such as DOTA and PCTA, as well as certain cryptands, were found to form kinetically inert complexes with the Ln3+ ions (and Y3+). Thus, the results reported in this work pave the way for a new generation of macrocyclic ligands for the stable complexation of these metal ions. In addition, the formation rates of the YL6 complex exceed those of YDOTA and rigidified YDTPA derivatives,23 and therefore ligand H3L6 could be especially valuable as a precursor for the design of yttrium-based radiopharmaceuticals.
On the other hand, according to the X-ray analyses and the calculations shown in this work, the resulting complexes tend to adopt geometries that favor the reduction of the macrocyclic cavity. Consequently, the ligand effectively wraps the metal ion, hindering the entrance of solvent molecules into the coordination sphere. As a result, quenching of luminescence is minimized for the TbL6 and EuL6 complexes, therefore meeting the key requirements for optical imaging applications.
In summary, ligand H3L6 exhibits appropriate characteristics to be considered a useful platform for the design of different types of diagnostic and/or therapeutic probes. Furthermore, the possibility of functionalizing the ligand through the benzyl moiety or replacing it with other groups expands the range of possible specific applications for systems derived from this one, resulting in a remarkably versatile ligand.
Experimental and Computational Section
General Considerations
NMR spectra were obtained at 25 and 70 °C on a Bruker Avance 300, Bruker Avance 400, or Bruker Avance 500 spectrometer. Elemental analyses were performed on a Thermo Finnigan Flash EA 1112 elemental analyzer. IR spectra were recorded using a Thermo Scientific FT-IR Nicolet iS10 spectrophotometer equipped with a Thermo Scientific Smart iTR attenuated total reflectance (ATR) accessory. Mass spectra were obtained either using an LC-Q-q-TOF Applied Biosystems QSTAR Elite spectrometer or an LTQ-Orbitrap Discovery mass spectrometer coupled to a Thermo Accela HPLC in ESI positive mode. Medium performance liquid chromatography (MPLC) was performed in a Puriflash XS 420 InterChim Chromatographer equipped with a UV-DAD detector and a 20 g BGB Aquarius C18AQ reversed-phase column (100 Å, spherical, 15 μm). Aqueous solutions of the final compounds were lyophilized in a Biobase BK-FD10 Series vacuum freeze dryer.
Absorption and Emission Spectra
UV–vis spectra were recorded on a Jasco V-650 spectrophotometer using 1 cm cells. Emission and excitation spectra were measured on a Horiba FluoroMax Plus-P spectrofluorometer equipped with a 150 W ozone-free xenon arc lamp and an R928P photon counting emission detector, as well as a photodiode reference detector for monitoring lamp output. Luminescence decays were measured on the same instrument working in the phosphorescence mode using a xenon flash lamp. Hydration numbers (q) were calculated using eq 6, where τH2O and τD2O represent the luminescence decay lifetimes in water and deuterated water, respectively. For TbL6, the hydration number was calculated using A = 5.0 and B = 0.06,63 while for EuL6, the reported hydration number corresponds to that obtained with A = 1.2 and B = 0.25.63 The use of A = 1.11 and B = 0.31 provides essentially the same result (q = −0.08).65
| 6 |
Luminescence quantum yields were obtained using Eu3+ and Tb3+ tris(dipicolinates) as references in solutions at 7.5 × 10–5 and 6.5 × 10–5 M, respectively (ϕEu = 0.24 and ϕTb = 0.22, λexc = 279 nm), while samples were measured at 1 × 10–4 M. Both the samples and the references were measured in 0.1 M Tris-buffered aqueous solutions at pH = 7.4.66,67
Dissociation and Formation Kinetics
Acid-catalyzed dissociation kinetics of YL6 were studied under pseudo-first-order conditions by the addition of concentrated HCl to an aqueous solution of the complex (2 × 10–5 M) at 25 °C. HCl concentration was varied in the range 0.1–2.4 M. Dissociation was followed by monitoring the decrease of the absorbance at 268 nm as a function of time using a Biochrom Libra S70 UV–vis spectrophotometer. The data were fitted to eq 7
| 7 |
where At, Ae, and Ao are the absorbance values measured at time t, at equilibrium, and at t = 0, respectively.
The formation of the YL6 complex was assessed by the addition of an excess of metal ion (10–40 equiv) to an aqueous solution of the ligand at 2 × 10–5 M and following the increase in absorbance at 275 nm over time until equilibrium was reached. Similarly, the formation of TbL6 was monitored by analyzing the emission intensity at 541 nm over time, with the aid of an SLM AMINCO Bowman series 2 luminescence spectrometer. The studies were performed in both cases at 25 °C with ionic strength adjusted to 0.1 M with KCl and N-methylpiperazine as a buffer to maintain the pH constant (4.7–5.4).
Syntheses
All solvents and reagents used were purchased from commercial sources, had reagent-grade quality, and were used as supplied, without further purification except for macrocycle 1, which was prepared according to the previously reported procedure.46
3-Benzyl-3,6,10,13-tetraaza-1,8(2,6)-dipyridinacyclotetradecaphane (2)
Compound 1 (0.2737 g, 0.84 mmol) was suspended in H2O (100 mL). The pH was lowered to 5 using 6 M HCl. As the pH is lowered, compound 1 dissolves completely. Benzyl bromide (0.1434, 0.84 mmol) was slowly added to the mixture, forming a suspension. The reaction mixture was then kept stirring at room temperature for 11 days, maintaining the pH between 5 and 6. The solvent was removed in a rotary evaporator to give a brown oil, which was dissolved in a mixture of H2O containing 0.1% of TFA (2 mL) and purified by MPLC using Method A (Table S2, Supporting Information). Compound eluted at 41% CH3CN, (retention time: 9.18 column volumes, 11:53 min:s). The combined fractions containing compound 2 were then freeze-dried obtaining 74.1 mg of a hygroscopic white-brown solid. Yield: 21%. 1H NMR (300 MHz, D2O): δ 8.0 (t, 1H), 7.9 (t, 1H), 7.4 (m, 9H), 4.6 (m, 6H), 4.5 (s, 2H), 4.4 (s, 2H), 3.8 (m, 8H). 13C{1H} NMR (75 MHz, D2O): δ 150.40, 150.23, 150.21, 149.83, 139.75, 139.62, 131.29, 129.31, 129.04, 128.15, 124.25, 123.03, 122.94, 58.38, 56.91, 50.91, 50.79, 43.91, 43.85, 42.31. MS (ESI+, %BPI): m/z 417.277 (100) ([C25H33N6]+), 439.258 (26) ([C25H32N6Na]+). Calc. for [C25H33N6]+: 417.276; [C25H32N6Na]+: 439.258.
2, 2′, 2″-(13-Benzyl-3,6,10,13-tetraaza-1,8(2,6)-dipyridinacyclotetradecaphane-3,6,10-triyl) Triacetic Acid (H3L6)
Compound 2 (0.065 g, 0.156 mmol) was dissolved in CH3CN (20 mL). K2CO3 (0.067 g, 0.484 mmol) and KI (2.59 mg, 0.0156 mmol) were added to the resulting mixture and, after stirring for 30 min, a solution of tert-butyl 2-bromoacetate (0.0913 g, 0.468 mmol) in acetonitrile (5 mL) was added dropwise over the course of 1 h. The mixture was stirred at room temperature for 3 days and then was concentrated to dryness. The resulting residue was dissolved in water (30 mL) and the pH of the solution was adjusted with NaOH to an approximate value of 13. This aqueous solution was extracted with chloroform (3 × 30 mL). The combined organic extracts were dried over Na2SO4 and evaporated to dryness, obtaining a brown oil. The resulting product was dissolved in a 1:1 CH2Cl2/TFA solution (3 mL) and stirred for 24 h at room temperature. The solvent was removed under a flow of nitrogen obtaining a brown residue that was washed with water (6 × 3 mL). This residue was then purified by reversed-phase MPLC method B (Table S3, Supporting Information). Compound eluted at 35% CH3CN, (retention time: 8.86 column volumes, 12:07 min:s). The combined fractions were freeze-dried obtaining 0.0392 g of H3L6 as a white powder. Yield: 28%. 1H NMR (400 MHz, D2O, pD = 1.0, 343 K) δ 8.8 (t, 1H), 8.4 (t, 1H), 8.2 (d, 2H), 7.9 (d, 1H), 7.8 (m, 6H), 5.2 (s, 2H), 5.0 (m, 6H), 5.0 (s, 2H), 4.4 (s, 2H), 4.3 (d, 6H), 4.1 (d, 4H), 4.1 (m, 2H). 13C{1H} NMR (126 MHz D2O, pD 1.0): δ 172.66, 170.82, 150.71, 150.18, 148.10, 140.03, 131.68, 130.32, 128.84, 127.53, 126.09, 124.84, 123.69, 123.16, 59.87, 58.80, 56.95, 56.61, 55.98, 55.71, 54.91, 53.26, 52.01, 50.33, 50.02. Elem. anal. found: C, 48.20; H, 4.48; N, 9.23. Calc. for C31H38N6O6·2.8TFA: C, 48.31; H, 4.52; N, 9.24. IR (ATR, cm–1): ν 2924, 2853 (C–H), 1725 (C=O), 1667 (C=N), 1457, 1397 (C=C), 1173, 1127 (C–O). MS (ESI+, %BPI): m/z 591.293 (100) ([C31H39N6O6]+), 629.240 (19) ([C31H38KN6O6]+), 613.275 (18) ([C31H38NaN6O6]+). Calc. For [C31H39N6O6]+: 591.293; [C31H38KN6O6]+: 629.248; ([C31H38NaN6O6]+): 613.275.
General Procedure for the Preparation of LnL6 Complexes
A mixture of H3L6 (0.075 g, 0.067 mmol) and DIPEA (0.063 g, 0.49 mmol) in 1-butanol (6 mL) was stirred for 30 min. Ln(OTf)3 (Ln = Eu, Tb) or YCl3·6H2O (0.067 mmol) was added to the solution, and the mixture was heated to reflux for 8 h. The solvent was removed in a rotary evaporator, and the resultant residue was purified by column chromatography (SiO2, CH3CN/H2O 14:3). The product obtained was dissolved in CH3CN (20 mL) and passed through a filter with a 0.22 μm pore size. The filtrate was concentrated to dryness and washed with diethyl ether.
EuL6: Yield: 0.036 g, 70%. Elem. anal. found: C, 46.64; H, 4.84; N, 9.32. Calc. for C31H35EuN6O6·3H2O: C, 46.91; H, 5.21; N, 10.59. MS (ESI+, %BPI): m/z 763.17 (100) ([C31H35EuN6NaO6]+), 741.19 (48) ([C31H36EuN6O6]+). HR-MS (ESI+): 741.1930. Calc. for [C31H36EuN6O6]+: 741.1903.
TbL6: Yield: 0.040 g, 74%. Elem. anal. found: C, 45.71; H, 5.25; N, 9.70. Calc. for C31H35N6O6Tb·4H2O: C, 45.48; H, 5.29; N, 10.27. MS (ESI+, %BPI): m/z 769.18 (100) ([C31H35N6NaO6Tb]+), 747.20 (20) ([C31H36N6O6Tb]+). HR-MS (ESI+): 747.1965. Calc. for [C31H36N6O6Tb]+: 747.1944.
YL6: Yield: 0.033 g, 66%. 1H NMR (D2O, pD = 7.5, 300 MHz): δ 7.92 (m, 2H), 7.46-7.24 (m, 9H), 4.86 (m, 1H), 4.35–3.91 (m, 7H), 3.74–3.52 (m, 4H), 3.35 (m, 3H), 3.16–2.63 (m, 7H), 2.46 (d, 1H), 1.29 (d, 1H). 13C{1H} NMR (D2O, pD = 7.5, 125.8 MHz): δ 181.5 (d, 2J = 2.1 Hz), 180.5, 179.5 (d, 2J = 2.0 Hz), 159.7, 159.4, 156.0, 155.1, 141.4, 140.5, 131.9, 131.4, 128.6, 128.4, 122.9, 122.6, 122.2, 120.1, 65.6, 64.8, 64.3, 63.1, 62.0, 61.7, 58.8, 57.9, 57.6, 54.9, 54.4, 53.1. Elem. anal. found: C, 49.61; H, 5.13; N, 10.43. Calc. for C31H35N6O6Y·4H2O: C, 49.74; H, 5.79; N, 11.23. MS (ESI+, %BPI): m/z 699.16 (100) ([C31H35N6NaO6Y]+), 677.18 (14) ([C31H36N6O6Y]+).HR-MS (ESI+): 677.1756. Calc. for [C31H36N6O6Y]+: 677.1749.
Crystal Structure Determinations
Crystallographic data were collected at 100 K using a Bruker D8 Venture diffractometer with a Photon 100 CMOS detector and Mo Kα radiation (λ = 0.71073 Å) generated by an Incoatec high-brilliance microfocus source equipped with Incoatec Helios multilayer optics. The software APEX388 was used for collecting frames of data, indexing reflections, and the determination of lattice parameters, SAINT89 for integration of intensity of reflections, and SADABS90 for scaling and empirical absorption correction. The structure was solved by dual-space methods using the program SHELXT.91 All nonhydrogen atoms were refined with anisotropic thermal parameters by full-matrix least-squares calculations on F2 using the program SHELXL-2014.92 Hydrogen atoms were inserted at calculated positions and constrained with isotropic thermal parameters. The OLEX2 solvent mask routine was used to delete highly disordered water molecules from the model in both structures. CCDC 2143076 and 2143077 contain the supplementary crystallographic data for YL6 and TbL6 respectively. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif. Table S4 contains the crystallographic data and the structure refinement parameters.
Computational Details
Full-geometry optimizations of the complexes studied in this work were performed using DFT within the hybrid meta-generalized gradient approximation with the TPSSh exchange–correlation functional93 and the Gaussian 09 package (Revision D.01).94 The ligand atoms were described using the standard 6-31G(d,p) basis set, while for the metal ions, an effective core potential (ECP) was employed to take into account the main relativistic effects and reduce the computational cost of the calculations. In the case of yttrium, the quasi-relativistic effective core potential ECP28MWB developed by Preuß and co-workers was used, along with its associated valence-basis set, which employs an (8s7p6d2f1g)/[6s5p3d2f1g]-GTO contraction scheme.95,96 The lanthanide ions were defined using the large-core quasi-relativistic effective core potential (LCRECP) created by Dolg and co-workers, which includes 46 + 4fn core electrons in the core (n = 6 for Eu3+ and n = 8 for Tb3+) and explicitly describes the 11 outer electrons (5s, 5p, 5d, and 6s). The valence electrons were described using the associated (7s 6p 5d)/[5s 4p 3d]-GTO basis set.97 The calculations were carried out in aqueous solutions and solvent effects were included making use of the integral-equation formalism variant of the polarizable continuum model (IEFPCM).98 As a starting point, molecular systems generated with GaussView99 were employed. Additionally, frequency analyses were performed on the optimized geometries to guarantee that they indeed correspond to energy minima rather than saddle points.
Using these optimized geometries, the 89Y NMR shielding tensors were calculated with the ORCA program package (version 4.2.1)100,101 utilizing the GIAO102,103 method and the TPSSh functional.93 Relativistic effects were considered applying the second-order Douglas–Kroll–Hess (DKH2) method,104,105 with the old-DKH-TZVPP basis set used by previous versions of ORCA consisting in a recontracted form of Ahlrichs’ TZVPPAll basis set106 for DKH2 calculations. The RIJK approximation, which considers both Coulomb and exchange-type integrals, was used for the calculation of the self-consistent field and the NMR chemical shielding constants.107−109 Auxiliary basis sets were constructed automatically by ORCA with the Autoaux procedure.110 The TightSCF and Grid7 (for Y) options were applied to increase the convergence tolerances and integration accuracies of the calculations from the defaults. Chemical shifts were determined as δ = (σref – σ) considering the shielding constant calculated for [Y(H2O)8]3+·16H2O as in ref (41). The calculations were carried out in aqueous solution and solvent effects were considered using the SMD solvation model.111
Radiolabeling Studies
Yttrium-90 chloride ([90Y]YCl3) was provided by PerkinElmer Life Sciences (Waltham, MA) in a 0.05 M HCl solution. The activity of the 90Y-solution comprised between 200 μCi and 1.2 mCi (7.5–45.5 MBq). Other chemicals (solvents, buffer solutions) were bought from Sigma-Aldrich (Saint-Louis, MO) and used as received. Experiments were performed in borosilicated sealed glass flasks. Sealed flasks were heated on a Bioblock heating block (Thermo Fisher, Waltham, MA). Activities were measured with a CRC-127R (Capintec, Inc., Ramsey, NJ) dose calibrator. Radiochemical yields (RCY) were determined by thin-layer chromatography (TLC) on Whatman 1 paper (GE Healthcare, Maidstone, U.K.) eluted in MeOH with 0.1% NEt3 and measured with a Cyclone Storage Phosphorimager (PerkinElmer, Waltham, MA), using the Optiquant software. HPLC analyses were performed on an HPLC Dionex Ultimate 3000 (Sunnyvale, CA) equipped with a diode array detector and a radiochromatographic fLumo (Berthold Technologies GmbH, Bad Wildbad, Germany) detector piloted by the Chromeleon software. The chromatographic analytic system employs an Accucore C18 100 × 3 mm2, 2.6 μm column with A = H2O; B = acetonitrile as eluents; 0–3 min: 100% A, 3–20 min: 0–90% B, 20–25 min: 90% B, 25–26 min: 90–0% B, 26–30 min: 100% A, at a flow rate of 0.4 mL/min.
90Y-Radiolabeling
Yttrium-90 is a pure high-energy β-emitting nuclide. Experiments were done in a controlled area adapted for the manipulations of such elements, by trained and suitably equipped and monitored operators (finger and chest dosimeters, direct reading personal device). Operations were done inside a high-energy hotcell, using dedicated high-energy tungsten shielding for vials, syringes, and telescopic pliers. Several parameters such as concentration of ligands, volume and pH of the reaction mixture, incubation time, and temperature were varied extensively to obtain an optimized protocol. An [90Y]YCl3 solution (0.2 mL) in 1 M glacial acetic acid solution (pH = 2.4) or in 3 M acetate buffer (pH = 4.65–9) was added to 0.2 mL of H3L6 ligand solution (c = 10 μM–1 mM) in ethanol. The resulting solution was heated at 20–100 °C for 5–60 min.
Stability of the [90Y]YL6 Radiochelate
For the challenging experiments, aliquots (0.2 mL) of [90Y]YL6 solution prepared under an optimized procedure were mixed with 0.2 mL of a 100 mM EDTA solution. The mixture was incubated at 37 °C under slight stirring and analyzed on TLC after 0, 1, 2, 5, 24, 48, and 120 h. Each sample was analyzed in triplicate.
For the stability study in serum, aliquots (0.2 mL) of [90Y]YL6 solution prepared under optimized procedure were mixed with 1 mL of a human serum. The mixture was incubated at 37 °C under slight stirring. A 100 μL aliquot was taken and, after denaturing serum protein with an equal amount of absolute ethanol and centrifugation (3500g, 4 °C, 15 min), the supernatant was analyzed on TLC after 24, 48, 72, 96, and 168 h. Each sample was analyzed in triplicate.
Acknowledgments
C.P.-I., and D.E.-G. thank Ministerio de Ciencia e Innovación (Grant PID2019-108352RJ-I00) and Xunta de Galicia (Grant ED431B 2020/52) for generous financial support. The authors are indebted to Centro de Supercomputación of Galicia (CESGA) for providing the computer facilities. C.H. thanks Ministerio de Ciencia e Innovación (Grant PRE2020-092888) and Xunta de Galicia (Grant ED481A 2021/070) for funding her PhD contracts. N.L. acknowledges Labex IRON (grant no. ANR-11-LABX-0018) and Guerbet for financial support. L.V. is indebted to CACTI (Universidade de Vigo) for X-ray measurements. Funding for open access provided by Universidade da Coruña/CISUG.
Supporting Information Available
The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.inorgchem.2c00378.
Luminescence lifetime decay curves; 1H, 13C, and 1H–1H COSY NMR spectra; high-resolution MS; kinetic experiments; absorption spectra; bond distances; and optimized geometries obtained with DFT (PDF)
Accession Codes
CCDC 2143076–2143077 contain the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: +44 1223 336033.
Author Contributions
The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.
The authors declare no competing financial interest.
Supplementary Material
References
- Franz K. J.; Metzler-Nolte N. Introduction: Metals in Medicine. Chem. Rev. 2019, 119, 727–729. 10.1021/acs.chemrev.8b00685. [DOI] [PubMed] [Google Scholar]
- Gaynor D.; Griffith D. M. The Prevalence of Metal-Based Drugs as Therapeutic or Diagnostic Agents: Beyond Platinum. Dalton Trans. 2012, 41, 13239–13257. 10.1039/C2DT31601C. [DOI] [PubMed] [Google Scholar]
- Guo Z.; Sadler P. J. Metals in Medicine. Angew. Chem., Int. Ed. 1999, 38, 1512–1531. . [DOI] [PubMed] [Google Scholar]
- Mewis R. E.; Archibald S. J. Biomedical Applications of Macrocyclic Ligand Complexes. Coord. Chem. Rev. 2010, 254, 1686–1712. 10.1016/j.ccr.2010.02.025. [DOI] [Google Scholar]
- Stasiuk G. J.; Long N. J. The Ubiquitous DOTA and Its Derivatives: The Impact of 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid on Biomedical Imaging. Chem. Commun. 2013, 49, 2732. 10.1039/c3cc38507h. [DOI] [PubMed] [Google Scholar]
- Clough T. J.; Jiang L.; Wong K.-L.; Long N. J. Ligand Design Strategies to Increase Stability of Gadolinium-Based Magnetic Resonance Imaging Contrast Agents. Nat. Commun. 2019, 10, 1420 10.1038/s41467-019-09342-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dai L.; Jones C. M.; Chan W. T. K.; Pham T. A.; Ling X.; Gale E. M.; Rotile N. J.; Tai W. C.-S.; Anderson C. J.; Caravan P.; Law G.-L. Chiral DOTA Chelators as an Improved Platform for Biomedical Imaging and Therapy Applications. Nat. Commun. 2018, 9, 857 10.1038/s41467-018-03315-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wahsner J.; Gale E. M.; Rodríguez-Rodríguez A.; Caravan P. Chemistry of MRI Contrast Agents: Current Challenges and New Frontiers. Chem. Rev. 2019, 119, 957–1057. 10.1021/acs.chemrev.8b00363. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Amoroso A. J.; Pope S. J. A. Using Lanthanide Ions in Molecular Bioimaging. Chem. Soc. Rev. 2015, 44, 4723–4742. 10.1039/C4CS00293H. [DOI] [PubMed] [Google Scholar]
- Hamon N.; Roux A.; Beyler M.; Mulatier J.-C.; Andraud C.; Nguyen C.; Maynadier M.; Bettache N.; Duperray A.; Grichine A.; Brasselet S.; Gary-Bobo M.; Maury O.; Tripier R. Pyclen-Based Ln(III) Complexes as Highly Luminescent Bioprobes for In Vitro and In Vivo One- and Two-Photon Bioimaging Applications. J. Am. Chem. Soc. 2020, 142, 10184–10197. 10.1021/jacs.0c03496. [DOI] [PubMed] [Google Scholar]
- Armelao L.; Quici S.; Barigelletti F.; Accorsi G.; Bottaro G.; Cavazzini M.; Tondello E. Design of Luminescent Lanthanide Complexes: From Molecules to Highly Efficient Photo-Emitting Materials. Coord. Chem. Rev. 2010, 254, 487–505. 10.1016/j.ccr.2009.07.025. [DOI] [Google Scholar]
- Coogan M. P.; Pope S. J. A.. Application of D- and f-Block Fluorescent Cell Imaging Agents. In The Chemistry of Molecular Imaging; John Wiley & Sons, Ltd., 2014; pp 275–298. [Google Scholar]
- Bünzli J. G. Lanthanide Luminescence for Biomedical Analyses and Imaging. Chem. Rev. 2010, 110, 2729–2755. 10.1021/cr900362e. [DOI] [PubMed] [Google Scholar]
- Horrocks W. D.; Sudnick D. R. Lanthanide Ion Probes of Structure in Biology. Laser-Induced Luminescence Decay Constants Provide a Direct Measure of the Number of Metal-Coordinated Water Molecules. J. Am. Chem. Soc. 1979, 101, 334–340. 10.1021/ja00496a010. [DOI] [Google Scholar]
- Wadas T. J.; Wong E. H.; Weisman G. R.; Anderson C. J. Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease. Chem. Rev. 2010, 110, 2858–2902. 10.1021/cr900325h. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jannin S.; Helm L.; Bodenhausen G. Kinetics of Yttrium–Ligand Complexation Monitored Using Hyperpolarized 89 Y as a Model for Gadolinium in Contrast Agents. J. Am. Chem. Soc. 2010, 132, 5006–5007. 10.1021/ja1013954. [DOI] [PubMed] [Google Scholar]
- Le Fur M.; Rotile N. J.; Correcher C.; Clavijo Jordan V.; Ross A. W.; Catana C.; Caravan P. Yttrium-86 Is a Positron Emitting Surrogate of Gadolinium for Noninvasive Quantification of Whole-Body Distribution of Gadolinium-Based Contrast Agents. Angew. Chem., Int. Ed. 2020, 59, 1474–1478. 10.1002/anie.201911858. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tickner B. J.; Stasiuk G. J.; Duckett S. B.; Angelovski G. The Use of Yttrium in Medical Imaging and Therapy: Historical Background and Future Perspectives. Chem. Soc. Rev. 2020, 49, 6169–6185. 10.1039/C9CS00840C. [DOI] [PubMed] [Google Scholar]
- Carter K. P.; Deblonde G. J.-P.; Lohrey T. D.; Bailey T. A.; An D. D.; Shield K. M.; Lukens W. W.; Abergel R. J. Developing Scandium and Yttrium Coordination Chemistry to Advance Theranostic Radiopharmaceuticals. Commun. Chem. 2020, 3, 61 10.1038/s42004-020-0307-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kostelnik T. I.; Orvig C. Radioactive Main Group and Rare Earth Metals for Imaging and Therapy. Chem. Rev. 2019, 119, 902–956. 10.1021/acs.chemrev.8b00294. [DOI] [PubMed] [Google Scholar]
- Boros E.; Packard A. B. Radioactive Transition Metals for Imaging and Therapy. Chem. Rev. 2019, 119, 870–901. 10.1021/acs.chemrev.8b00281. [DOI] [PubMed] [Google Scholar]
- Zeglis B. M.; Lewis J. S. A Practical Guide to the Construction of Radiometallated Bioconjugates for Positron Emission Tomography. Dalton Trans. 2011, 40, 6168–6195. 10.1039/C0DT01595D. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Price E. W.; Orvig C. Matching Chelators to Radiometals for Radiopharmaceuticals. Chem. Soc. Rev. 2014, 43, 260–290. 10.1039/c3cs60304k. [DOI] [PubMed] [Google Scholar]
- Löble M. W.; Casimiro M.; Thielemann D. T.; Oña-Burgos P.; Fernández I.; Roesky P. W.; Breher F. 1H,89Y HMQC and Further NMR Spectroscopic and X-Ray Diffraction Investigations on Yttrium-Containing Complexes Exhibiting Various Nuclearities. Chem. - Eur. J. 2012, 18, 5325–5334. 10.1002/chem.201102636. [DOI] [PubMed] [Google Scholar]
- Merritt M. E.; Harrison C.; Kovacs Z.; Kshirsagar P.; Malloy C. R.; Sherry A. D. Hyperpolarized 89Y Offers the Potential of Direct Imaging of Metal Ions in Biological Systems by Magnetic Resonance. J. Am. Chem. Soc. 2007, 129, 12942–12943. 10.1021/ja075768z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jindal A. K.; Merritt M. E.; Suh E. H.; Malloy C. R.; Sherry A. D.; Kovács Z. Hyperpolarized 89Y Complexes as Ph Sensitive NMR Probes. J. Am. Chem. Soc. 2010, 132, 1784–1785. 10.1021/ja910278e. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lumata L.; Merritt M.; Malloy C.; Sherry A. D.; Kovacs Z. Fast Dissolution Dynamic Nuclear Polarization NMR of 13C-Enriched 89Y-DOTA Complex: Experimental and Theoretical Considerations. Appl. Magn. Reson. 2012, 43, 69–79. 10.1007/s00723-012-0335-8. [DOI] [Google Scholar]
- Lumata L.; Jindal A. K.; Merritt M. E.; Malloy C. R.; Sherry A. D.; Kovacs Z. DNP by Thermal Mixing under Optimized Conditions Yields>60 000-Fold Enhancement of 89Y NMR Signal. J. Am. Chem. Soc. 2011, 133, 8673–8680. 10.1021/ja201880y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang Q.; Parish C.; Niedbalski P.; Ratnakar J.; Kovacs Z.; Lumata L. Hyperpolarized 89Y-EDTMP Complex as a Chemical Shift-Based NMR Sensor for Ph at the Physiological Range. J. Magn. Reson. 2020, 320, 106837 10.1016/j.jmr.2020.106837. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rezaeivala M.; Keypour H. Schiff Base and Non-Schiff Base Macrocyclic Ligands and Complexes Incorporating the Pyridine Moiety – The First 50 Years. Coord. Chem. Rev. 2014, 280, 203–253. 10.1016/j.ccr.2014.06.007. [DOI] [Google Scholar]
- Le Fur M.; Molnár E.; Beyler M.; Fougère O.; Esteban-Gómez D.; Rousseaux O.; Tripier R.; Tircsó G.; Platas-Iglesias C. Expanding the Family of Pyclen-Based Ligands Bearing Pendant Picolinate Arms for Lanthanide Complexation. Inorg. Chem. 2018, 57, 6932–6945. 10.1021/acs.inorgchem.8b00598. [DOI] [PubMed] [Google Scholar]
- Garda Z.; Molnár E.; Hamon N.; Barriada J. L.; Esteban-Gómez D.; Váradi B.; Nagy V.; Pota K.; Kálmán F. K.; Tóth I.; Lihi N.; Platas-Iglesias C.; Tóth É.; Tripier R.; Tircsó G. Complexation of Mn(II) by Rigid Pyclen Diacetates: Equilibrium, Kinetic, Relaxometric, Density Functional Theory, and Superoxide Dismutase Activity Studies. Inorg. Chem. 2021, 60, 1133–1148. 10.1021/acs.inorgchem.0c03276. [DOI] [PubMed] [Google Scholar]
- Nizou G.; Favaretto C.; Borgna F.; Grundler P. V.; Saffon-Merceron N.; Platas-Iglesias C.; Fougère O.; Rousseaux O.; van der Meulen N. P.; Müller C.; Beyler M.; Tripier R. Expanding the Scope of Pyclen-Picolinate Lanthanide Chelates to Potential Theranostic Applications. Inorg. Chem. 2020, 59, 11736–11748. 10.1021/acs.inorgchem.0c01664. [DOI] [PubMed] [Google Scholar]
- Kim W. D.; Kiefer G. E.; Maton F.; McMillan K.; Muller R. N.; Sherry A. D. Relaxometry, Luminescence Measurement, Electrophoresis, and Animal Biodistribution of Lanthanide(III) Complexes of Some Polyaza Macrocyclic Acetates Containing Pyridine. Inorg. Chem. 1995, 34, 2233–2243. 10.1021/ic00112a041. [DOI] [Google Scholar]
- Miao L.; Bell D.; Rothremel G. L.; Bryant L. H.; Fitzsimmons P. M.; Jackels S. C. Design and Synthesis of an “Ultrachelating” Ligand Based on an 18-Membered Ring Hexaaza Macrocycle. Supramol. Chem. 1996, 6, 365–373. 10.1080/10610279608032556. [DOI] [Google Scholar]
- Valencia L.; Martinez J.; Macías A.; Bastida R.; Carvalho R. A.; Geraldes C. F. G. C. X-Ray Diffraction and 1H NMR in Solution: Structural Determination of Lanthanide Complexes of a Py2N6Ac4 Ligand. Inorg. Chem. 2002, 41, 5300–5312. 10.1021/ic0257017. [DOI] [PubMed] [Google Scholar]
- Bligh S. W. A.; Choi N.; Geraldes C. F. G. C.; Knoke S.; McPartlin M.; Sanganee M. J.; Woodroffe T. M. A Novel Hexaaza Macrocycle with Methylenephosphonate Pendant Arms: A Potential Useful Chelate for Biomedical Applications†. J. Chem. Soc., Dalton Trans. 1997, 0, 4119–4126. 10.1039/A703678G. [DOI] [Google Scholar]
- Núñez C.; Bastida R.; Macías A.; Mato-Iglesias M.; Platas-Iglesias C.; Valencia L. A Hexaaza Macrocyclic Ligand Containing Acetohydrazide Pendants for Ln(III) Complexation in Aqueous Solution. Solid-State and Solution Structures and DFT Calculations. Dalton Trans. 2008, 102, 3841–3850. 10.1039/B800953H. [DOI] [PubMed] [Google Scholar]
- del C. Fernández-Fernández M.; Bastida R.; Macías A.; Pérez-Lourido P.; Platas-Iglesias C.; Valencia L. Lanthanide(III) Complexes with a Tetrapyridine Pendant-Armed Macrocyclic Ligand: 1H NMR Structural Determination in Solution, X-Ray Diffraction, and Density-Functional Theory Calculations. Inorg. Chem. 2006, 45, 4484–4496. 10.1021/ic0603508. [DOI] [PubMed] [Google Scholar]
- Castro G.; Regueiro-Figueroa M.; Esteban-Gómez D.; Bastida R.; Macías A.; Pérez-Lourido P.; Platas-Iglesias C.; Valencia L. Exceptionally Inert Lanthanide(III) PARACEST MRI Contrast Agents Based on an 18-Membered Macrocyclic Platform. Chem. - Eur. J. 2015, 21, 18662–18670. 10.1002/chem.201502937. [DOI] [PubMed] [Google Scholar]
- Castro G.; Wang G.; Gambino T.; Esteban-Gómez D.; Valencia L.; Angelovski G.; Platas-Iglesias C.; Pérez-Lourido P. Lanthanide(III) Complexes Based on an 18-Membered Macrocycle Containing Acetamide Pendants. Structural Characterization and ParaCEST Properties. Inorg. Chem. 2021, 60, 1902–1914. 10.1021/acs.inorgchem.0c03385. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gambino T.; Valencia L.; Pérez-Lourido P.; Esteban-Gómez D.; Zaiss M.; Platas-Iglesias C.; Angelovski G. Inert Macrocyclic Eu 3+ Complex with Affirmative ParaCEST Features. Inorg. Chem. Front. 2020, 7, 2274–2286. 10.1039/C9QI01612K. [DOI] [Google Scholar]
- Nonat A.; Esteban-Gómez D.; Valencia L.; Pérez-Lourido P.; Barriada J. L.; Charbonnière L. J.; Platas-Iglesias C. The Role of Ligand to Metal Charge-Transfer States on the Luminescence of Europium Complexes with 18-Membered Macrocyclic Ligands. Dalton Trans. 2019, 48, 4035–4045. 10.1039/C8DT05005H. [DOI] [PubMed] [Google Scholar]
- Price E. W.; Zeglis B. M.; Cawthray J. F.; Ramogida C. F.; Ramos N.; Lewis J. S.; Adam M. J.; Orvig C. H4octapa-Trastuzumab: Versatile Acyclic Chelate System for 111In and 177Lu Imaging and Therapy. J. Am. Chem. Soc. 2013, 135, 12707–12721. 10.1021/ja4049493. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Farrugia L. J. WinGX and ORTEP for Windows: An Update. J. Appl. Crystallogr. 2012, 45, 849–854. 10.1107/S0021889812029111. [DOI] [Google Scholar]
- Rothermel G. L.; Miao L.; Hill A. L.; Jackels S. C. Macrocyclic Ligands with 18-Membered Rings Containing Pyridine or Furan Groups: Preparation, Protonation, and Complexation by Metal Ions. Inorg. Chem. 1992, 31, 4854–4859. 10.1021/ic00049a025. [DOI] [Google Scholar]
- Ferreirós-Martínez R.; Esteban-Gómez D.; Platas-Iglesias C.; de Blas A.; Rodríguez-Blas T. Zn(II), Cd(II) and Pb(II) Complexation with Pyridinecarboxylate Containing Ligands. Dalton Trans. 2008, 17, 5754–5765. 10.1039/B808631A. [DOI] [PubMed] [Google Scholar]
- Carter K. P.; Pope S. J. A.; Cahill C. L. A Series of Ln-p-Chlorobenzoic Acid–Terpyridine Complexes: Lanthanide Contraction Effects, Supramolecular Interactions and Luminescent Behavior. CrystEngComm 2014, 16, 1873–1884. 10.1039/C3CE42267D. [DOI] [Google Scholar]
- Lewis F. W.; Harwood L. M.; Hudson M. J.; Drew M. G. B.; Modolo G.; Sypula M.; Desreux J. F.; Bouslimani N.; Vidick G. Interaction of 6,6″-Bis(5,5,8,8-Tetramethyl-5,6,7,8-Tetrahydro-1,2,4-Benzotriazin-3-yl)-2,2′:6′,2′′-Terpyridine (CyMe4-BTTP) with Some Trivalent Ions Such as Lanthanide(III) Ions and Americium(III). Dalton Trans. 2010, 39, 5172–5182. 10.1039/B924988E. [DOI] [PubMed] [Google Scholar]
- Kiefer G. E.; Woods M. Solid State and Solution Dynamics of Pyridine Based Tetraaza-Macrocyclic Lanthanide Chelates Possessing Phosphonate Ligating Functionality (Ln-PCTMB): Effect on Relaxometry and Optical Properties. Inorg. Chem. 2009, 48, 11767–11778. 10.1021/ic901779k. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Le Fur M.; Beyler M.; Lepareur N.; Fougère O.; Platas-Iglesias C.; Rousseaux O.; Tripier R. Pyclen Tri- n -Butylphosphonate Ester as Potential Chelator for Targeted Radiotherapy: From Yttrium(III) Complexation to 90 Y Radiolabeling. Inorg. Chem. 2016, 55, 8003–8012. 10.1021/acs.inorgchem.6b01135. [DOI] [PubMed] [Google Scholar]
- Kumar K.; Chang C. A.; Francesconi L. C.; Dischino D. D.; Malley M. F.; Gougoutas J. Z.; Tweedle M. F. Synthesis, Stability, and Structure of Gadolinium(III) and Yttrium(III) Macrocyclic Poly(Amino Carboxylates). Inorg. Chem. 1994, 33, 3567–3575. 10.1021/ic00094a021. [DOI] [Google Scholar]
- Kotek J.; Rudovský J.; Hermann P.; Lukeš I. Three in One: TSA, TSA‘, and SA Units in One Crystal Structure of a Yttrium(III) Complex with a Monophosphinated H4dota Analogue. Inorg. Chem. 2006, 45, 3097–3102. 10.1021/ic060006a. [DOI] [PubMed] [Google Scholar]
- Lau E. Y.; Lightstone F. C.; Colvin M. E. Environmental Effects on the Structure of Metal Ion–DOTA Complexes: An Ab Initio Study of Radiopharmaceutical Metals. Inorg. Chem. 2006, 45, 9225–9232. 10.1021/ic0602897. [DOI] [PubMed] [Google Scholar]
- Caravan P.; Ellison J. J.; McMurry T. J.; Lauffer R. B. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem. Rev. 1999, 99, 2293–2352. 10.1021/cr980440x. [DOI] [PubMed] [Google Scholar]
- Casanova D.; Cirera J.; Llunell M.; Alemany P.; Avnir D.; Alvarez S. Minimal Distortion Pathways in Polyhedral Rearrangements. J. Am. Chem. Soc. 2004, 126, 1755–1763. 10.1021/ja036479n. [DOI] [PubMed] [Google Scholar]
- Cirera J.; Ruiz E.; Alvarez S. Shape and Spin State in Four-Coordinate Transition-Metal Complexes: The Case of the D6 Configuration. Chem. - Eur. J. 2006, 12, 3162–3167. 10.1002/chem.200501516. [DOI] [PubMed] [Google Scholar]
- Pinsky M.; Avnir D. Continuous Symmetry Measures. 5. The Classical Polyhedra. Inorg. Chem. 1998, 37, 5575–5582. 10.1021/ic9804925. [DOI] [PubMed] [Google Scholar]
- Ruiz-Martínez A.; Casanova D.; Alvarez S. Polyhedral Structures with an Odd Number of Vertices: Nine-Atom Clusters and Supramolecular Architectures. Dalton Trans. 2008, 99, 2583–2591. 10.1039/B718821H. [DOI] [PubMed] [Google Scholar]
- Ruiz-Martínez A.; Casanova D.; Alvarez S. Polyhedral Structures with an Odd Number of Vertices: Nine-Coordinate Metal Compounds. Chem. - Eur. J. 2008, 14, 1291–1303. 10.1002/chem.200701137. [DOI] [PubMed] [Google Scholar]
- Richardson F. S. Terbium(III) and Europium(III) Ions as Luminescent Probes and Stains for Biomolecular Systems. Chem. Rev. 1982, 82, 541–552. 10.1021/cr00051a004. [DOI] [Google Scholar]
- Binnemans K. Interpretation of Europium(III) Spectra. Coord. Chem. Rev. 2015, 295, 1–45. 10.1016/j.ccr.2015.02.015. [DOI] [Google Scholar]
- Beeby A.; Clarkson I. M.; Dickins R. S.; Faulkner S.; Parker D.; Royle L.; Sousa A. S.; de Williams J. A. G.; Woods M. Non-Radiative Deactivation of the Excited States of Europium, Terbium and Ytterbium Complexes by Proximate Energy-Matched OH, NH and CH Oscillators: An Improved Luminescence Method for Establishing Solution Hydration States. J. Chem. Soc., Perkin Trans. 2 1999, 2, 493–504. 10.1039/A808692C. [DOI] [Google Scholar]
- Sabbatini N.; Guardigli M.; Lehn J.-M. Luminescent Lanthanide Complexes as Photochemical Supramolecular Devices. Coord. Chem. Rev. 1993, 123, 201–228. 10.1016/0010-8545(93)85056-A. [DOI] [Google Scholar]
- Supkowski R. M.; Horrocks W. D. On the Determination of the Number of Water Molecules, q, Coordinated to Europium(III) Ions in Solution from Luminescence Decay Lifetimes. Inorg. Chim. Acta 2002, 340, 44–48. 10.1016/S0020-1693(02)01022-8. [DOI] [Google Scholar]
- Chauvin A.; Frédéric G.; Daniel I.; Bünzli J. G. Europium and Terbium Tris(Dipicolinates) as Secondary Standards for Quantum Yield Determination. Spectrosc. Lett. 2004, 37, 517–532. 10.1081/SL-120039700. [DOI] [Google Scholar]
- Chauvin A.; Gumy F.; Imbert D.; Bünzli J.-C. G. Erratum: Europium and Terbium Tris (Dipicolinates) as Secondary Standards for Quantum Yield Determination. Spectrosc. Lett. 2007, 40, 193. 10.1080/00387010601158480. [DOI] [Google Scholar]
- Enomoto K.; LaVerne J. A.; Seki S.; Tagawa S. Formation and Decay of the Triplet Excited State of Pyridine. J. Phys. Chem. A 2006, 110, 9874–9879. 10.1021/jp0632539. [DOI] [PubMed] [Google Scholar]
- Latva M.; Takalob H.; Mukkala V.-M.; Matachescu C.; Rodriguez-Ubisd J. C.; Kankarea J. Correlation between the Lowest Triplet State Energy Level of the Ligand and Lanthanide(III) Luminescence Quantum Yield. J. Lumin. 1997, 75, 149–16921. 10.1016/S0022-2313(97)00113-0. [DOI] [Google Scholar]
- Nonat A.; Gateau C.; Fries P. H.; Mazzanti M. Lanthanide Complexes of a Picolinate Ligand Derived from 1,4,7-Triazacyclononane with Potential Application in Magnetic Resonance Imaging and Time-Resolved Luminescence Imaging. Chem. - Eur. J. 2006, 12, 7133–7150. 10.1002/chem.200501390. [DOI] [PubMed] [Google Scholar]
- Nocton G.; Nonat A.; Gateau C.; Mazzanti M. Water Stability and Luminescence of Lanthanide Complexes of Tripodal Ligands Derived from 1,4,7-Triazacyclononane: Pyridinecarboxamide versus Pyridinecarboxylate Donors. Helv. Chim. Acta 2009, 92, 2257–2273. 10.1002/hlca.200900150. [DOI] [Google Scholar]
- Regueiro-Figueroa M.; Bensenane B.; Ruscsák E.; Esteban-Gómez D.; Charbonnière L. J.; Tircsó G.; Tóth I.; Blas A.; de Rodríguez-Blas T.; Platas-Iglesias C. Lanthanide Dota-like Complexes Containing a Picolinate Pendant: Structural Entry for the Design of LnIII-Based Luminescent Probes. Inorg. Chem. 2011, 50, 4125–4141. 10.1021/ic2001915. [DOI] [PubMed] [Google Scholar]
- Guanci C.; Giovenzana G.; Lattuada L.; Platas-Iglesias C.; Charbonnière L. J. AMPED: A New Platform for Picolinate Based Luminescent Lanthanide Chelates. Dalton Trans. 2015, 44, 7654–7661. 10.1039/C5DT00077G. [DOI] [PubMed] [Google Scholar]
- Cosby A. G.; Quevedo G.; Boros E. A High-Throughput Method To Measure Relative Quantum Yield of Lanthanide Complexes for Bioimaging. Inorg. Chem. 2019, 58, 10611–10615. 10.1021/acs.inorgchem.9b01786. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Werts M. H. V.; Jukes R. T. F.; Verhoeven J. W. The Emission Spectrum and the Radiative Lifetime of Eu3+ in Luminescent Lanthanide Complexes. Phys. Chem. Chem. Phys. 2002, 4, 1542–1548. 10.1039/B107770H. [DOI] [Google Scholar]
- Shavaleev N. M.; Eliseeva S. V.; Scopelliti R.; Bünzli J.-C. G. Influence of Symmetry on the Luminescence and Radiative Lifetime of Nine-Coordinate Europium Complexes. Inorg. Chem. 2015, 54, 9166–9173. 10.1021/acs.inorgchem.5b01580. [DOI] [PubMed] [Google Scholar]
- Leygue N.; Picard C.; Faure P.; Bourrier E.; Lamarque L.; Zwier J. M.; Galaup C. Design of Novel Tripyridinophane-Based Eu(III) Complexes as Efficient Luminescent Labels for Bioassay Applications. Org. Biomol. Chem. 2021, 20, 182–195. 10.1039/D1OB02092G. [DOI] [PubMed] [Google Scholar]
- Piccinelli F.; Rosa C. D.; Melchior A.; Faura G.; Tolazzi M.; Bettinelli M. Eu(III) and Tb(III) Complexes of 6-Fold Coordinating Ligands Showing High Affinity for the Hydrogen Carbonate Ion: A Spectroscopic and Thermodynamic Study. Dalton Trans. 2019, 48, 1202–1216. 10.1039/C8DT03621G. [DOI] [PubMed] [Google Scholar]
- Di Pietro S.; Iacopini D.; Moscardini A.; Bizzarri R.; Pineschi M.; Di Bussolo V.; Signore G. New Coumarin Dipicolinate Europium Complexes with a Rich Chemical Speciation and Tunable Luminescence. Molecules 2021, 26, 1265. 10.3390/molecules26051265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Isaac M.; Denisov S. A.; McClenaghan N. D.; Sénèque O. Bioinspired Luminescent Europium-Based Probe Capable of Discrimination between Ag + and Cu +. Inorg. Chem. 2021, 60, 10791–10798. 10.1021/acs.inorgchem.1c01486. [DOI] [PubMed] [Google Scholar]
- Kofod N.; Nielsen L. G.; Sørensen T. J. Temperature Dependence of Fundamental Photophysical Properties of [Eu(MeOH-d4)9] 3+ Solvates and [Eu·DOTA(MeOH-d4)] – Complexes. J. Phys. Chem. A 2021, 125, 8347–8357. 10.1021/acs.jpca.1c04994. [DOI] [PubMed] [Google Scholar]
- Xing Y.; Jindal A. K.; Regueiro-Figueroa M.; Le Fur M.; Kervarec N.; Zhao P.; Kovacs Z.; Valencia L.; Pérez-Lourido P.; Tripier R.; Esteban-Gómez D.; Platas-Iglesias C.; Sherry A. D. The Relationship between NMR Chemical Shifts of Thermally Polarized and Hyperpolarized 89Y Complexes and Their Solution Structures. Chem. - Eur. J. 2016, 22, 16657–16667. 10.1002/chem.201602901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tircsó G.; Kovács Z.; Sherry A. D. Equilibrium and Formation/Dissociation Kinetics of Some LnIIIPCTA Complexes. Inorg. Chem. 2006, 45, 9269–9280. 10.1021/ic0608750. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Burai L.; Fábián I.; Király R.; Szilágyi E.; Brücher E. Equilibrium and Kinetic Studies on the Formation of the Lanthanide(III) Complexes, [Ce(Dota)]– and [Yb(Dota)]– (H4dota = 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid). J. Chem. Soc., Dalton Trans. 1998, No 2, 243–248. 10.1039/A705158A. [DOI] [Google Scholar]
- Pulukkody K. P.; Norman T. J.; Parker D.; Royle L.; Broan C. J. Synthesis of Charged and Uncharged Complexes of Gadolinium and Yttrium with Cyclic Polyazaphosphinic Acid Ligands for in Vivo Applications. J. Chem. Soc., Perkin Trans. 2 1993, No 4, 605. 10.1039/p29930000605. [DOI] [Google Scholar]
- Tircsó G.; Benyó E. T.; Suh E. H.; Jurek P.; Kiefer G. E.; Sherry A. D.; Kovács Z. (S)-5-(p-Nitrobenzyl)-PCTA, a Promising Bifunctional Ligand with Advantageous Metal Ion Complexation Kinetics. Bioconjugate Chem. 2009, 20, 565–575. 10.1021/bc8004914. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pandey U.; Mukherjee A.; Sarma H. D.; Das T.; Pillai M. R. A.; Venkatesh M. Evaluation of 90Y-DTPA and 90Y-DOTA for Potential Application in Intra-Vascular Radionuclide Therapy. Appl. Radiat. Isot. 2002, 57, 313–318. 10.1016/S0969-8043(02)00103-3. [DOI] [PubMed] [Google Scholar]
- APEX3, Version 2016.1.; Bruker AXS Inc., 2016.
- SAINT, Version 8.37A; Bruker AXS Inc., 2015.
- Sheldrick G. M.SADABS, Version 2014/5; Bruker AXS Inc.
- Sheldrick G. M. Crystal Structure Refinement with SHELXL. Acta Crystallogr., Sect. C: Struct. Chem. 2015, 71, 3–8. 10.1107/S2053229614024218. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sheldrick G. M. A Short History of SHELX. Acta Crystallogr., Sect. A: Found. Crystallogr. 2008, 64, 112–122. 10.1107/S0108767307043930. [DOI] [PubMed] [Google Scholar]
- Tao J.; Perdew J. P.; Staroverov V. N.; Scuseria G. E. Climbing the Density Functional Ladder: Nonempirical Meta--Generalized Gradient Approximation Designed for Molecules and Solids. Phys. Rev. Lett. 2003, 91, 146401 10.1103/PhysRevLett.91.146401. [DOI] [PubMed] [Google Scholar]
- Frisch M. J.; Trucks G. W.; Schlegel H. B.; Scuseria G. E.; Robb M. A.; Cheeseman J. R.; Scalmani G.; Barone V.; Petersson G. A.; Nakatsuji H.; Li X.; Caricato M.; Marenich A. V.; Bloino J.; Janesko B. G.; Gomperts R.; Mennucci B.; Hratchian H. P.; Ortiz J. V.; Izmaylov A. F.; Sonnenberg J. L.; Williams-Young D.; Ding F.; Lipparini F.; Egidi F.; Goings J.; Peng B.; Petrone A.; Henderson T.; Ranasinghe D.; Zakrzewski V. G.; Gao J.; Rega N.; Zheng G.; Liang W.; Hada M.; Ehara M.; Toyota K.; Fukuda R.; Hasegawa J.; Ishida M.; Nakajima T.; Honda Y.; Kitao O.; Nakai H.; Vreven T.; Throssell K.; Montgomery J. A. Jr; Peralta J. E.; Ogliaro F.; Bearpark M. J.; Heyd J. J.; Brothers E. N.; Kudin K. N.; Staroverov V. N.; Keith T. A.; Kobayashi R.; Normand J.; Raghavachari K.; Rendell A. P.; Burant J. C.; Iyengar S. S.; Tomasi J.; Cossi M.; Millam J. M.; Klene M.; Adamo C.; Cammi R.; Ochterski J. W.; Martin R. L.; Morokuma K.; Farkas O.; Foresman J. B.; Fox D. J.. Gaussian 09, Revision D.01.
- Andrae D.; Häußermann U.; Dolg M.; Stoll H.; Preuß H. Energy-Adjusted Ab Initio Pseudopotentials for the Second and Third Row Transition Elements. Theor. Chim. Acta 1990, 77, 123–141. 10.1007/BF01114537. [DOI] [Google Scholar]
- Martin J. M. L.; Sundermann A. Correlation Consistent Valence Basis Sets for Use with the Stuttgart–Dresden–Bonn Relativistic Effective Core Potentials: The Atoms Ga–Kr and In–Xe. J. Chem. Phys. 2001, 114, 3408–3420. 10.1063/1.1337864. [DOI] [Google Scholar]
- Dolg M.; Stoll H.; Savin A.; Preuss H. Energy-Adjusted Pseudopotentials for the Rare Earth Elements. Theor. Chim. Acta 1989, 75, 173–194. 10.1007/BF00528565. [DOI] [Google Scholar]
- Tomasi J.; Mennucci B.; Cammi R. Quantum Mechanical Continuum Solvation Models. Chem. Rev. 2005, 105, 2999–3094. 10.1021/cr9904009. [DOI] [PubMed] [Google Scholar]
- Dennington R.; Keith T.; Millam J.. GaussView 5, 2009.
- Neese F. The ORCA Program System. WIREs Comput. Mol. Sci. 2012, 2, 73–78. 10.1002/wcms.81. [DOI] [Google Scholar]
- Neese F. Software Update: The ORCA Program System, Version 4.0. WIREs Comput. Mol. Sci. 2018, 8, e1327 10.1002/wcms.1327. [DOI] [Google Scholar]
- Ditchfield R. Molecular Orbital Theory of Magnetic Shielding and Magnetic Susceptibility. J. Chem. Phys. 1972, 56, 5688–5691. 10.1063/1.1677088. [DOI] [Google Scholar]
- Helgaker T.; Jaszuński M.; Ruud K. Ab Initio Methods for the Calculation of NMR Shielding and Indirect Spin–Spin Coupling Constants. Chem. Rev. 1999, 99, 293–352. 10.1021/cr960017t. [DOI] [PubMed] [Google Scholar]
- Barysz M.; Sadlej A. J. Two-Component Methods of Relativistic Quantum Chemistry: From the Douglas–Kroll Approximation to the Exact Two-Component Formalism. J. Mol. Struct.: THEOCHEM 2001, 573, 181–200. 10.1016/S0166-1280(01)00542-5. [DOI] [Google Scholar]
- Reiher M. Douglas–Kroll–Hess Theory: A Relativistic Electrons-Only Theory for Chemistry. Theor. Chem. Acc. 2006, 116, 241–252. 10.1007/s00214-005-0003-2. [DOI] [Google Scholar]
- Ahlrichs R.; May K. Contracted All-Electron Gaussian Basis Sets for Atoms Rb to Xe. Phys. Chem. Chem. Phys. 2000, 2, 943–945. 10.1039/A908859H. [DOI] [Google Scholar]
- Kossmann S.; Neese F. Comparison of Two Efficient Approximate Hartee–Fock Approaches. Chem. Phys. Lett. 2009, 481, 240–243. 10.1016/j.cplett.2009.09.073. [DOI] [Google Scholar]
- Weigend F.; Kattannek M.; Ahlrichs R. Approximated Electron Repulsion Integrals: Cholesky Decomposition versus Resolution of the Identity Methods. J. Chem. Phys. 2009, 130, 164106 10.1063/1.3116103. [DOI] [PubMed] [Google Scholar]
- Stoychev G. L.; Auer A. A.; Izsák R.; Neese F. Self-Consistent Field Calculation of Nuclear Magnetic Resonance Chemical Shielding Constants Using Gauge-Including Atomic Orbitals and Approximate Two-Electron Integrals. J. Chem. Theory Comput. 2018, 14, 619–637. 10.1021/acs.jctc.7b01006. [DOI] [PubMed] [Google Scholar]
- Stoychev G. L.; Auer A. A.; Neese F. Automatic Generation of Auxiliary Basis Sets. J. Chem. Theory Comput. 2017, 13, 554–562. 10.1021/acs.jctc.6b01041. [DOI] [PubMed] [Google Scholar]
- Marenich A. V.; Cramer C. J.; Truhlar D. G. Universal Solvation Model Based on Solute Electron Density and on a Continuum Model of the Solvent Defined by the Bulk Dielectric Constant and Atomic Surface Tensions. J. Phys. Chem. B 2009, 113, 6378–6396. 10.1021/jp810292n. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.



